Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Aurora Cannabis Inc

While Investors Chase Monday's Tilray, Canopy And Aurora Rally, A Potential Federal Shift Could Redefine Cannabis Growth Fundamentals

Shares of major cannabis companies, including Tilray Brands Inc (NASDAQ:TLRY), Canopy Growth Corp (NASDAQ:CGC), and Aurora Cannabis Inc (NASDAQ:ACB), are trading sharply higher Monday morning.

Benzinga

Aurora Cannabis (ACB) vs. Merck (MRK): Which Pharma Stock Holds Greater Potential for Investors?

The pharmaceutical industry is poised for robust growth owing to technological advancements and growing healthcare needs. Given this backdrop, let’s analyze Aurora Cannabis (ACB) and Merck & Co. (MRK) to determine which of the two stocks holds greater potential for investors. Read on….

StockNews.com

Which of these 3 Pharma Stocks Should You Buy, Hold or Sell?

The pharmaceutical industry is well-positioned for long-term growth thanks to rising investments in drug development and technological advancements. So, let's analyze whether Johnson & Johnson (JNJ), Calliditas Therapeutics AB (CALT), and Aurora Cannabis (ACB) are a Buy, Hold, or Sell.

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

2 Cannabis Stocks Not Worth the Smoke

Despite its remarkable growth during the pandemic, the cannabis industry's current trajectory has been marred by legal, economic, and sector-wide hurdles. This has cast a pall over the industry’s outlook. Therefore, fundamentally weak stocks Aurora Cannabis (ACB) and IM Cannabis (IMCC) might be avoided now. Continue reading….

StockNews.com

Sell the Farm on These 4 Cannabis Stocks

Despite significant growth in recent years driven by increased legalization, the cannabis industry took a hit last year amid economic and industry-wide headwinds, including stubborn supply gluts. Furthermore, the industry will likely remain under pressure this year due to economic challenges. Hence, it could be wise to avoid fundamentally weak…

StockNews.com

Marijuana Stocks: Buy or Sell These 3 in 2023?

Although several states have legalized marijuana, the industry faces a supply glut amid high inflation impacting overall demand. With Federal legalization unlikely this year, marijuana stocks could remain under pressure. Therefore, would it be wise to invest in marijuana stocks Tilray Brands (TLRY), Canopy Growth (CGC), and Aurora Cannabis (ACB)…

StockNews.com

4 Marijuana Stocks to Avoid Like the Plague

While marijuana legalization has been rising, the industry is witnessing increased regulations. Moreover, the sector’s revenues have been declining recently. Hence, marijuana stocks Tilray Brands (TLRY), Canopy Growth (CGC), Sundial Growers (SNDL), and Aurora Cannabis (ACB) might be best avoided, given their weak fundamentals and negative profit margins. Keep reading.

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

Aurora Shares Plunge On Q4 Earnings Report But This Analyst Sees Better Days Ahead, Here's Why

Aurora Cannabis Inc. (NASDAQ: ACB) reported its financial and operational results for the fourth quarter and fiscal year ending June 30, 2022

Benzinga

Aurora Cannabis Reports 2022 Q4 Earnings: Revenue Flat Sequentially At C$50.2M, CEO Optimistic

Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), a Canadian global company in the cannabis industry, serving both the medical and consumer markets; recently announced its financial and operational results for the fourth quarter a

Benzinga

3 Cannabis Stocks Going up in Flames to Avoid

The wide use of cannabis for recreational activities and its increased medicinal use has helped the market gain traction over the past years. However, with legalization barriers worldwide, this industry is in an odd limbo in which consumption flourishes, but penalties and taxes still prevail. Given the backdrop, it should…

StockNews.com

Aurora Cannabis Acquires Controlling Interest In Greenhouse Tech Experts, Bevo Farms

Aurora Cannabis Inc.

Benzinga

Read Why Cantor Upgraded Aurora Cannabis Stock

Cantor Fitzgerald has upgraded Aurora Cannabis Inc (NASDAQ: ACB) to Overweight from Neutral

Benzinga

Aurora Cannabis Announces More Layoffs, Here's Why

Aurora Cannabis Inc. (NASDAQ: ACB) continues to trim its workforce as it seeks to achieve profitability.

Benzinga

Is Aurora Cannabis a Buy Under $2?

With its stock currently trading at less than $2, Aurora Cannabis (ACB) has strengthened its portfolio and made considerable progress in the worldwide medicinal cannabis market. However, given that the company is struggling to generate revenue growth in the consumer cannabis segment, is it worth buying the stock now? Read…

StockNews.com

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Aurora Cannabis Repurchases $20M Of Convertible Notes

Aurora Cannabis Inc. (NASDAQ: ACB) (TSX:ACB), has repurchased an aggregate of approximately CA$25.3 million ($20 million) principal amount of its convertible senior notes at a total cost, including accrued interest, of CA$24.3 million ($19.2 million) in cash.

Benzinga

Aurora Cannabis Closes $172.5M Bought Deal Financing, Here Are The Details

Aurora Cannabis Inc. (NASDAQ: ACB) (TSX:ACB) closed bought deal offering of units of the company for gross proceeds of approximately $172.5 million. The company sold approximately 70.4 million units at a price of $2.45 per unit, including approximately 9.2 million units sold pursuant to the

Benzinga

Aurora Cannabis Upsizes Bought Deal Financing

Aurora Cannabis Inc. (NASDAQ: ACB) (TSX:ACB), has amended the terms of its previously announced bought deal financing.

Benzinga

Why Aurora Cannabis Stock Is Getting Hammered Today

Aurora Cannabis Inc. (NASDAQ: ACB) shares are trading lower after the company announced it has enetered into a bought deal financing agreement. Aurora announced today that it has amended the terms of its previously announced bought deal financing.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Aurora Cannabis Announces $125M Bought Deal Financing

Aurora Cannabis Inc.

Benzinga

Aurora Gets EU-GMP Certification For Its Cannabis Production Facility In Germany

Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB) has received EU-GMP certification for its state-of-the-art medical cannabis production facility in Germany.

Benzinga

Why Should Investors Keep An Eye On Aurora Cannabis Stock Despite A Weak Quarter?

Aurora Cannabis Inc. (NASDAQ: ACB) reported financial and operational results late Thursday for the third quarter of fiscal 2022 ended March 31, 2022.

Benzinga

Aurora Cannabis Reports Fiscal 2022 Q3 Results, Net Revenue $50.4M

Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), a Canadian cannabis company, announced its financial and operational results late Thursday for the third quarter of fiscal 2022 ended March 31, 2022.

StockNews.com

2 Cannabis Stocks to Avoid After Stifel Cuts Their Price Targets

Surging inflation and the Fed’s hawkish monetary policy stance could keep the stock market under pressure in the near term. Amid the uncertainties surrounding the economy and the stock market, Stifel analysts are maintaining a negative outlook on the cannabis industry and have cut their price targets for the stocks…

Benzinga

Aurora Cannabis Completes Acquisition Of Thrive Cannabis

Aurora Cannabis Inc.

Benzinga

EXCLUSIVE: Aurora Cannabis CEO 'Absolutely Confident' Company Will Be EBITDA-Positive By Year's End

Miguel Martin, CEO of Aurora Cannabis Inc (NASDAQ: ACB), discussed growing Aurora into the leader of the international medical cannabis market at the Benzinga Cannabis Capital Conference on Wednesday.

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Medical Pharmaceuticals

125 stories

TLRY

99 stories

Medical – Pharmaceuticals

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.